MindSave Official Website › Notebook › The B-Vitamin Trial Behind This Label

The B-Vitamin Trial Behind This Label

By MindSave Team · Last updated September 26, 2026 · 9 min read · Cognition labels

This notebook already covers the tolerable upper limits on niacin and vitamin B6. What it has not covered is the one large, well-conducted trial that actually measured whether a B vitamin does anything to the brain — and it is a more specific, more conditional result than a label's “supports cognitive health” framing would suggest.

The trial behind the vitamin

Homocysteine is an amino acid the body produces as a normal metabolic byproduct, and elevated blood levels of it are an established risk factor for brain atrophy, cognitive impairment and dementia. B vitamins, taken together, are one of the few interventions known to reliably lower it. The VITACOG trial, published in 2010, set out to test whether lowering homocysteine this way could actually slow the rate of brain shrinkage that comes with aging and mild cognitive impairment.

It was a single-centre, randomised, double-blind, placebo-controlled trial of 271 people, drawn from 646 screened, all over 70 years old and all diagnosed with mild cognitive impairment. Participants were assigned to two years of daily folic acid (0.8 mg), vitamin B12 (0.5 mg) and vitamin B6 (20 mg), or to a matching placebo. A subset of 187 volunteered for MRI brain scans at the start and end of the study; 168 completed both scans, 85 in the treatment group and 83 on placebo.

What the brain scans showed

The primary outcome was the rate of whole-brain atrophy measured by serial volumetric MRI. The active-treatment group's brain volume shrank at a mean rate of 0.76% a year; the placebo group shrank at 1.08% a year, a difference that reached statistical significance (p = 0.001). That is a real, MRI-measured, statistically significant slowing of brain shrinkage over a two-year randomised trial — a stronger category of evidence than almost anything else discussed on any page in this notebook.

The effect was not uniform across participants, and the trial's own analysis says so directly. The rate of atrophy in people whose baseline homocysteine was above 13 µmol/L was 53% lower in the active-treatment group than placebo (p = 0.001). The paper does not report an equivalent benefit for people who started with lower, unremarkable homocysteine levels. Serious adverse events did not differ between the groups.

A seven-fold difference, in one region

A 2013 follow-up analysis of the same trial, published in the Proceedings of the National Academy of Sciences, went further than the whole-brain measurement. That paper looked specifically at gray-matter regions known to be vulnerable to Alzheimer's-related atrophy, including the medial temporal lobe, and found B-vitamin treatment reduced atrophy in those regions by as much as seven-fold compared with placebo. As with the whole-brain result, this benefit was confined to participants whose baseline homocysteine sat above the study's median of 11 µmol/L; in the placebo group, higher starting homocysteine predicted faster gray-matter loss, and B-vitamin treatment largely prevented that. A causal-pathway analysis in the same paper traced a specific chain: B vitamins lower homocysteine, lower homocysteine leads directly to less gray-matter atrophy, and less atrophy is associated with slower cognitive decline.

The cognitive and clinical follow-up

A third paper from the same trial reported the secondary cognitive and clinical outcomes. Across the whole sample, mean plasma homocysteine was 30% lower in the B-vitamin group than placebo, and B vitamins stabilised a measure of executive function (the CLOX test) relative to placebo (p = 0.015). Again, the clearer wins were concentrated in the higher-homocysteine participants: among those above the study median, B-vitamin treatment showed significant benefit on the Mini-Mental State Examination (p < 0.001), on delayed recall in an episodic-memory test (p = 0.001), and on a category-fluency test of semantic memory (p = 0.037). Among the quarter of participants with the highest baseline homocysteine, there was also a measurable clinical benefit on a global dementia-rating scale (p = 0.02) and on an informant-reported cognitive-decline questionnaire (p = 0.01).

The paper's own conclusion is careful rather than sweeping: in this small intervention trial, B vitamins appeared to slow cognitive and clinical decline in people with mild cognitive impairment, particularly those with elevated homocysteine, and further trials were called for to see whether the same treatment could delay or prevent progression to dementia.

All three papers report on the same 271-person VITACOG cohort. None of them tested vitamin B6 in isolation, and none of them describes MindSave.

The Smith 2010 paper frames why a trial like this was worth running at all: an estimated sixteen percent of people over 70 have mild cognitive impairment, and about half of those go on to develop Alzheimer's disease. Accelerated brain atrophy is itself a marker of that conversion, which is why slowing it in a randomised trial, rather than merely observing an association in a cohort, was the specific contribution this trial made. The authors were careful to frame their own findings as a reason for further trials rather than a settled recommendation, specifically ones aimed at whether the same treatment could delay or prevent the shift from mild cognitive impairment to full dementia.

It is worth setting that finding against a broader verdict on the same class of nutrients. The National Center for Complementary and Integrative Health states plainly that vitamin B6, vitamin B12 and folic acid have not been shown to improve cognitive functioning in older adults generally. That is not a contradiction of VITACOG so much as a scope difference: the broader statement describes B vitamins given without regard to a person's homocysteine status, while VITACOG's positive results were concentrated entirely in people selected, in effect, by an elevated homocysteine reading. A vitamin that does little for an unselected population can still do something real for a specific, identifiable subgroup within it, and telling those two claims apart is the entire point of reading the subgroup analysis rather than only the topline result.

Three vitamins, not one

This is the point worth being exact about. VITACOG did not test vitamin B6 alone. It tested folic acid, vitamin B12 and vitamin B6 together, at 0.8 mg, 0.5 mg and 20 mg a day respectively, and the causal chain its authors describe runs through homocysteine, a marker all three vitamins act on together. Nothing in this trial isolates what B6 alone would have done at any dose, let alone at whatever amount MindSave's undisclosed capsule might contain. This notebook's own vitamin page already states the reference figures: vitamin B6 carries a recommended intake around 1.3 to 1.7 mg a day and a tolerable upper limit of 100 mg a day from food and supplements combined, so the 20 mg used in this trial sits comfortably within that upper limit, but well above what a single capsule in an eight-ingredient blend is likely to be contributing.

Who this trial actually describes

Every meaningful result in VITACOG, across all three published papers, was strongest or exclusive to participants aged over 70, already diagnosed with mild cognitive impairment, and starting with blood homocysteine above the study's own median or threshold. That is a specific, at-risk, older clinical population identified by a blood test most people have never had run. It is not a description of a healthy adult reaching for a once-daily cognition capsule with no diagnosis and no known homocysteine level, and the trial's authors do not claim otherwise anywhere in the papers cited here.

What this means for a once-daily capsule

Vitamin B6 is not evidence-free on this label the way some names arguably are. It sits inside one of the more rigorous trial records of anything discussed in this notebook: randomised, placebo-controlled, MRI-verified, with a plausible and tested biological mechanism running through homocysteine. But that record describes a three-vitamin combination, at a specific higher dose than a proprietary blend is likely to provide, tested in older adults with diagnosed cognitive impairment and elevated homocysteine specifically. MindSave's sales page makes no homocysteine claim, states no dose for vitamin B6, and does not restrict its marketing to people over 70 with mild cognitive impairment. The trial and the label are, in a fairly literal sense, talking about two different things that happen to share one vitamin's name.